Compare Autodesk Inc (ADSK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs Recursion Pharmaceuticals Inc — how do they compare? Autodesk Inc trades at $246.62 (market cap $53.12B), while Recursion Pharmaceuticals Inc trades at $3.27 (market cap $1.81B). The key difference: Autodesk Inc is far larger — about 29.3× Recursion Pharmaceuticals Inc's market cap, and Autodesk Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | RXRX | |
|---|---|---|
Market Cap | $53.12B | $1.81B |
Sector | Technology | Health |
52-Week High | $326.79 | $6.79 |
52-Week Low | $187.72 | $2.84 |
Enterprise Value | $52.92B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $256.07, up 2.81% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $4.4B in 2022 to $6.1B in 2025, net income margin expanding to 19.49%, and consistent earnings beats. Recent news highlights AI investments and upcoming Q2 2027 earnings call on August 27, 2026.
Outlook remains positive with 74.5% analyst buy ratings and $302.23 consensus target offering 18% upside. Key risks include elevated valuation multiples (P/E 36.73) and competitive pressures in design software. The stock's technical strength and fundamental growth trajectory support continued investor interest despite overbought RSI signals.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
